Adaptive Biotechnologies ‘scratching the surface’ in its quest to create a disease-by-disease map of T cell receptors to antigens
Adaptive Biotechnologies’ platform applies proprietary chemistry, computational biology, and machine learning to read the genetic code of a patient’s immune system, with the goal of translating insights from the adaptive immune system into diagnostics and drugs. [Adaptive Biotechnologies]
Adaptive’s platform applies proprietary chemistry, computational biology, and machine learning to read the genetic code of a patient’s immune system. The platform takes the key cells of the adaptive immune system that enable the body to mount responses against antigens—T cells and B cells—extracts and sequences their genomic DNA, then identifies the receptor sequences that are contained within those cells . . .
